Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
December 2024
in “
Allergy
”
Studysummary This study found that tralokinumab effectively reduced the severity of moderate-to-severe atopic dermatitis over 28 weeks in adults, with significant improvements in clinical outcomes and biological markers, although 27.4% of patients discontinued treatment due to adverse events or ineffectiveness.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on onlinelibrary.wiley.com →